3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Sarcoma
1
Conditions
Brain Neoplasms
3
Urinary Bladder Neoplasms
1
Sarcoma, Ewing
1
Rhabdomyosarcoma
1
Prostatic Neoplasms
1
Osteosarcoma
1
Osteonecrosis
1
Osteomyelitis
1
Lung Carcinoma Metastatic in the Brain
1
Kidney Neoplasms
1
Glioblastoma
1
Cranial Nerve Diseases
1
Chondrosarcoma
1
Central Nervous System Neoplasms
1
Bone Neoplasms
1
Interventions
Gemcitabine
5
Nivolumab
3
Irinotecan
3
Ipilimumab
3
Docetaxel
3
Cyclophosphamide
3
3-(5-fluorobenzofuran-3-yl)-4-(5-methyl-5H-(1,3)dioxolo(4,5-f)indol-7-yl)-pyrrole-2,5-dione
3
pegfilgrastim
2
Vincristine
2
Temozolomide
2
Ibandronic Acid
2
Everolimus
2
Doxorubicin
2
CTLA-4 Antigen
2
spartalizumab
1
saracatinib
1
samarium Sm-153 lexidronam
1
pembrolizumab
1
palbociclib
1
liposomal doxorubicin
1
lenvatinib
1
fludarabine
1
anlotinib
1
angiotensin I (1-7)
1
aldesleukin
1
Zoledronic Acid
1
Trabectedin
1
Topotecan
1
Taxes
1
Sunitinib
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 2
×
Bone Neoplasms
×
Ferrosoferric Oxide
×
Clear all
NCT01336803
2023-12-27
Osteosarcoma
Stanford University
Phase 2
Completed
32 enrolled
11 charts